Poly-Ligand Profiling differentiates pancreatic cancer patients according to treatment benefit from gemcitabine+placebo versus gemcitabine+evofosfamide and identifies candidate targets

V. Domenyuk; X. Liu; D. Magee; Z. Gatalica; A. Stark; P. Kennedy; M. Rosenow; A. Barker; D. Berry; G. Poste; D. Halbert; C. Hart; M. Famulok; G. Mayer; M. Korn; M. Miglarese; D. Spetzler

doi:10.1093/annonc/mdy151.131

Poly-Ligand Profiling differentiates pancreatic cancer patients according to treatment benefit from gemcitabine+placebo versus gemcitabine+evofosfamide and identifies candidate targets

V. Domenyuk, X. Liu, D. Magee, Z. Gatalica, A. Stark, P. Kennedy, M. Rosenow, A. Barker, D. Berry, G. Poste, D. Halbert, C. Hart, M. Famulok, G. Mayer, M. Korn, M. Miglarese, D. Spetzler

Complex Adaptive Systems (CAS)

Research output: Contribution to journal › Article › peer-review

202 Scopus citations

Original language	English (US)
Pages (from-to)	v36
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy151.131
State	Published - Jun 1 2018

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdy151.131

Cite this

Domenyuk, V., Liu, X., Magee, D., Gatalica, Z., Stark, A., Kennedy, P., Rosenow, M., Barker, A., Berry, D., Poste, G., Halbert, D., Hart, C., Famulok, M., Mayer, G., Korn, M., Miglarese, M., & Spetzler, D. (2018). Poly-Ligand Profiling differentiates pancreatic cancer patients according to treatment benefit from gemcitabine+placebo versus gemcitabine+evofosfamide and identifies candidate targets. Annals of oncology : official journal of the European Society for Medical Oncology, 29, v36. https://doi.org/10.1093/annonc/mdy151.131

Poly-Ligand Profiling differentiates pancreatic cancer patients according to treatment benefit from gemcitabine+placebo versus gemcitabine+evofosfamide and identifies candidate targets. / Domenyuk, V.; Liu, X.; Magee, D. et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.06.2018, p. v36.

Research output: Contribution to journal › Article › peer-review

Domenyuk, V, Liu, X, Magee, D, Gatalica, Z, Stark, A, Kennedy, P, Rosenow, M, Barker, A, Berry, D, Poste, G, Halbert, D, Hart, C, Famulok, M, Mayer, G, Korn, M, Miglarese, M & Spetzler, D 2018, 'Poly-Ligand Profiling differentiates pancreatic cancer patients according to treatment benefit from gemcitabine+placebo versus gemcitabine+evofosfamide and identifies candidate targets', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. v36. https://doi.org/10.1093/annonc/mdy151.131

Domenyuk V, Liu X, Magee D, Gatalica Z, Stark A, Kennedy P et al. Poly-Ligand Profiling differentiates pancreatic cancer patients according to treatment benefit from gemcitabine+placebo versus gemcitabine+evofosfamide and identifies candidate targets. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Jun 1;29:v36. doi: 10.1093/annonc/mdy151.131

@article{d04cdb0939df4a4aa43a894a25bb3c2c,

title = "Poly-Ligand Profiling differentiates pancreatic cancer patients according to treatment benefit from gemcitabine+placebo versus gemcitabine+evofosfamide and identifies candidate targets",

author = "V. Domenyuk and X. Liu and D. Magee and Z. Gatalica and A. Stark and P. Kennedy and M. Rosenow and A. Barker and D. Berry and G. Poste and D. Halbert and C. Hart and M. Famulok and G. Mayer and M. Korn and M. Miglarese and D. Spetzler",

year = "2018",

month = jun,

day = "1",

doi = "10.1093/annonc/mdy151.131",

language = "English (US)",

volume = "29",

pages = "v36",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Poly-Ligand Profiling differentiates pancreatic cancer patients according to treatment benefit from gemcitabine+placebo versus gemcitabine+evofosfamide and identifies candidate targets

AU - Domenyuk, V.

AU - Liu, X.

AU - Magee, D.

AU - Gatalica, Z.

AU - Stark, A.

AU - Kennedy, P.

AU - Rosenow, M.

AU - Barker, A.

AU - Berry, D.

AU - Poste, G.

AU - Halbert, D.

AU - Hart, C.

AU - Famulok, M.

AU - Mayer, G.

AU - Korn, M.

AU - Miglarese, M.

AU - Spetzler, D.

PY - 2018/6/1

Y1 - 2018/6/1

UR - http://www.scopus.com/inward/record.url?scp=85070090823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070090823&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy151.131

DO - 10.1093/annonc/mdy151.131

M3 - Article

C2 - 32177111

SN - 0923-7534

VL - 29

SP - v36

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

ER -

Poly-Ligand Profiling differentiates pancreatic cancer patients according to treatment benefit from gemcitabine+placebo versus gemcitabine+evofosfamide and identifies candidate targets

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this